Targeting epigenetic enzymes in core binding factor AML [ 2017 - ]

Research Grant

Researchers: Prof Ricky Johnstone (Principal investigator) ,  Dr Michael Dickinson ,  Prof Miles Prince

Brief description Acute myeloid leukemia (AML) is a devastating disease and there are ~900 new cases diagnosed annually in Australia. A subset of AML, called core binding factor (CBF) AML is more responsive to conventional chemotherapies than other AMLs however patients still relapse indicating a need for new therapies. We will use preclinical models of CBF AML to identify the proteins and pathways that these leukemias are “addicted” to in order to develop new treatment options for these patients.

Funding Amount $542,273.00

Funding Scheme Project Grants

Notes Standard Project Grant